RBC Capital lowered the firm’s price target on CorMedix to $9 from $10 but keeps an Outperform rating on the shares. The company’s Q4 results saw consistent messaging and incremental updates on launch and reimbursement strategy regarding the reaffirmed proposed April 15th in-patient launch and a potential July outpatient launch for DefenCath in catheter-related blood stream infections prevention in hemodialysis, the analyst tells investors in a research note. The firm is also updating its model with new quarterly numbers and uptake assumptions, RBC stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRMD:
- Cormedix Inc.’s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient Market Adoption
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- CorMedix expects cash to fund operations for at least 12 months
- CorMedix reports Q4 EPS (26c), consensus (20c)